Boehringer, Sanofi partner to produce monoclonal antibodies
The deal is expected to strengthen Sanofi’s manufacturing capacity to support upcoming product launches. Currently, 72% of Sanofi’s research and development (R&D) projects are in biologics, nearly half
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.